Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2013 - 2019)
Ultragenyx Pharmaceutical (RARE) posted quarterly Current Deferred Revenue of $69000.0 for Q1 2019, down 90.46% year-over-year from $723000.0 in Q1 2018, and down 94.45% quarter-over-quarter from $1.2 million in Q2 2018.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2013 - 2019) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Current Deferred Revenue for 7 consecutive years, with $69000.0 the latest figure, recorded in Q1 2019.
- In Q1 2019, Current Deferred Revenue fell 90.46% year-over-year to $69000.0; the TTM figure through Mar 2019 stood at $69000.0 (down 90.46% YoY), while the FY2017 annual figure was $6.0 million, up 1655.43% from the prior year.
- Current Deferred Revenue slipped to $69000.0 in Q1 2019 per RARE's latest filing, from $1.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $6.0 million in Q4 2017 and bottomed at $69000.0 in Q1 2019.
- Historically, Current Deferred Revenue has averaged $794000.0 across 5 years, with a median of $328000.0 in 2016.
- Annual changes were most pronounced in 2017 — Current Deferred Revenue soared 1655.43% — and 2019, when it tumbled 90.46%.
- Ultragenyx Pharmaceutical's Current Deferred Revenue stood at $192000.0 in 2015, then surged by 77.6% to $341000.0 in 2016, then jumped by 1655.43% to $6.0 million in 2017, then sank by 79.22% to $1.2 million in 2018, then tumbled by 94.45% to $69000.0 in 2019.
- Business Quant data shows RARE's Current Deferred Revenue at $69000.0 in Q1 2019, $1.2 million in Q2 2018, and $723000.0 in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2019 | 69,000.00 |
| Jun 30, 2018 | 1.24 Mn |
| Mar 31, 2018 | 723,000.00 |
| Dec 31, 2017 | 5.99 Mn |
| Sep 30, 2017 | 695,000.00 |
| Jun 30, 2017 | 669,000.00 |
| Mar 31, 2017 | 637,000.00 |
| Dec 31, 2016 | 341,000.00 |
| Sep 30, 2016 | 328,000.00 |
| Jun 30, 2016 | 315,000.00 |
| Mar 31, 2016 | 303,000.00 |
| Dec 31, 2015 | 192,000.00 |
| Sep 30, 2015 | 163,000.00 |
| Jun 30, 2015 | 155,000.00 |
| Mar 31, 2015 | 90,000.00 |
| Dec 31, 2014 | 85,000.00 |
| Sep 30, 2014 | 80,000.00 |
| Jun 30, 2014 | 75,000.00 |
| Mar 31, 2014 | 78,000.00 |
| Dec 31, 2013 | 78,000.00 |